NCT00183989终止2 期
A Pilot Phase II Trial of Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 30
- 试验地点
- 2
研究概览
简要总结
This study is being done in order to determine the effectiveness of the combination of fludarabine, mitoxantrone, and rituximab in patients with mantle cell lymphoma. All three drugs,fludarabine, mitoxantrone, and rituximab have been approved by the U.S. Food and Drug Administration (FDA)for the treatment of certain types of lymphoma. Rituximab is a drug (called a monoclonal antibody) which has anti-tumor activity on certain types of lymphoma. The combination of chemotherapy (fludarabine and mitoxantrone) with rituximab has not yet been investigated in patients with mantle cell lymphoma and therefore the combination in investigational.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologic diagnosis of Non-Hodgkin's Lymphoma of the mantle cell sub-type lymphoma only, as determined by morphologic assessment and consistent immunophemotypic markers
- •Newly diagnosed and patients who have received prior treatment are eligible
- •Measurable or evaluable disease
- •Karnofsky performance status greater or equal to 50%
- •Men and women, age greater or equal to 18 years old
- •AGC greater or equal to 1.0; platelets greater or equal to 75,000; Hemoglobin greater or equal to 8.0 (unless because of lymphomatous infiltration of the marrow)
- •Creatinine less than 2.0; bilirubin less than 2.0; SGOT less than 3 times upper limit of normal (unless elevations are due to lymphomatous involvement)
- •Women of child bearing potential must have negative pregnancy test within 14 days of study entry.
- •Signed informed consent
排除标准
- •History of congestive heart failure or significant cardiac disease
- •Prior exposure to either fludarabine or mitoxantrone. Prior exposure to rituximab allowed
- •Active infection
- •HIV seropositive
- •Pregnant or lactating females
- •Second active malignancy, other than squamous cell skin cancer,in-situ cervical cancer, or history of other cancer diagnosed within the preceding 5 years
- •Presence of psychological or emotional disorders which would make valid informed consent impossible
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.Acute Myeloid Leukemia, AdultAML, AdultAMLNCT04425655University of California, San Diego2
已完成
2 期
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 YearsChronic Lymphocytic LeukemiaNCT00254410M.D. Anderson Cancer Center30
已完成
2 期
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDSAcute Myelogenous LeukemiaMyelodysplastic SyndromesChronic Myelogenous LeukemiaNCT00334074Baylor Research Institute30
撤回
2 期
A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid LeukemiaRelapsed/Refractory FLT3-mutated AMLNCT03324243Arog Pharmaceuticals, Inc.
招募中
2 期
Study of addition of fludarabine to the standard regimen of Anti-thymocyte globulin (ATG) and cyclosporine in patients with aplastic anemia (condition that occurs when the body stops producing enough new blood cells)CTRI/2014/06/004676INVESTIGATOR INITIATED STUDY20